Home » Topics » BioWorld Science

BioWorld Science
RSS

KY-455: Kyoto Pharm.'s ACAT/lipid peroxidation inhibitor

May 3, 1996

Ligand, Pfizer settle lawsuit related to osteoporosis drugs

May 3, 1996

Teijin reports vitamin D3 derivatives for osteoporosis

May 3, 1996

Verteporfin effective in treating severe age-related macular degeneration in early trials

May 3, 1996

Toray's MIP for treatment of ophthalmological disorders

May 3, 1996

EPC-K claimed for ophthalmic use

May 3, 1996

Hybridon reports oligonucleotide MDR inhibitors

May 3, 1996

Vertex dedicates significant efforts to MDR-reversing agents

May 3, 1996

Allovectin-7 clinical results announced at AACR

May 3, 1996

Receptagen will develop vitamin B12 uptake inhibitors

May 3, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...